From retroviral vector production to gene transfer: Spontaneous inactivation is caused by loss of reverse transcription capacity

Journal of Gene Medicine

Volumn 10, Issue 4, 2008, Pages 383-391

  Carmo, M ^a   Panet, A ^b   Carrondo, M J T ^a,c   Alves, P M ^a   Cruz, P E ^a  

^a INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^b HEBREW UNIVERSITY   (Israel)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Gene transfer; Inactivation; Retroviral vectors; Reverse transcription; Stabilization

Indexed keywords

DNA POLYMERASE; RETROVIRUS VECTOR; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; VIRUS RNA; VIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; DRUG STABILITY; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE THERAPY; GENE TRANSFER; HEAT SENSITIVITY; HUMAN; HUMAN CELL; MURINE LEUKEMIA VIRUS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; RNA DEGRADATION; RNA STABILITY; TEMPERATURE; VIRUS INACTIVATION; VIRUS INFECTIVITY;

CELL LINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HUMANS; LEUKEMIA VIRUS, MURINE; REVERSE TRANSCRIPTION; RIBONUCLEASE H; RNA STABILITY; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; VIRUS INACTIVATION;

MURINE LEUKEMIA VIRUS;

EID: 42049091745     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1163     Document Type: Article

References (31)

1. McTaggart S, Al-Rubeai M. Retroviral vectors for human gene delivery. Biotechnol Adv 2002; 20: 1-31.
2. Pages JC, Bru T. Toolbox for retrovectorologists. J Gene Med 2004; 6: S67-S82.
3. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358.
4. Andreadis ST, Roth CM, Le Doux JM, Morgan JR, Yarmush ML. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 1999, 15: 1-11.
5. Cruz PE, Silva AC, Roldao A, Carmo M, Carrondo MJ, Alves PM. Screening of novel excipients for improving the stability of retroviral and adenoviral vectors. Biotechnol Prog 2006; 22: 568-576.
6. Whitcomb JM, Hughes SH. Retroviral reverse transcription and integration: progress and problems. Annu Rev Cell Biol 1992; 8: 275-306.
7. Coffin JM, Hughes SH, Varmus HE (eds). Retroviruses. Cold Spring Harbor Laboratory Press: New York, NY, 1997.
8. Whiting SH, Champoux JJ. Properties of strand displacement synthesis by Moloney murine leukemia virus reverse transcriptase: mechanistic implications. J Mol Biol 1998; 278: 559-577.
9. Pizzato M, Merten OW, Blair ED, Takeuchi Y. Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. Gene Ther 2001; 8: 737-745.
10. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stornatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033-8037.
11. Landazuri N, Gupta M, Le Doux JM. Rapid concentration and purification of retrovirus by flocculation with Polybrene, J Biotechnol 2006; 125: 529-539.
12. Carmo M, Faria TQ, Falk H, et al. Relationship between retroviral vector membrane and vector stability. J Gen Virol 2006; 87: 1349-1356.
13. Haseltine WA, Coffin JM, Hageman TC. Structure of products of the Moloney murine leukemia virus endogenous DNA polymerase reaction. J Virol 1979; 30: 375-383.
14. Fassati A, Goff SP. Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus. J Virol 1999; 73: 8919-8925.
15. Carmo M, Peixoto C, Coroadinha AS, Alves PM, Cruz PE, Carrondo MJ. Quantitation of MLV-based retroviral vectors using real-time RT-PCR. J Virol Methods 2004; 119: 115-119.
16. Julias JG, Ferris AL, Boyer PL, Hughes SH. Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J Virol 2001; 75: 6537-6546.
17. Parniak MA, Min KL, Budihas SR, Le Grice SF, Bender JA. A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal Biochem 2003; 322: 33-39.
18. Schultz SJ, Whiting SH, Champoux JJ. Cleavage specificities of Moloney murine leukemia virus RNase H implicated in the second strand transfer during reverse transcription. J Biol Chem 1995; 270: 24135-24145.
19. Chen J, Reeves L, Sanburn N, Croop J, Williams DA, Cornetta K. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research. Virology 2001; 282: 186-197.
20. Trono D. Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol 1992; 66: 4893-4900.
21. Zhu J, Cunningham JM. Minus-strand DNA is present within murine type C ecotropic retroviruses prior to infection. J Virol 1993; 67: 2385-2388.
22. Ben-Artzi H, Zeelon E, Amit B, Wortzel A, Gorecki M, Panet A. RNase H activity of reverse transcriptases on substrates derived from the 5′ end of retroviral genome. J Biol Chem 1993; 268: 16465-16471.
23. Kim SY, Byrn R, Groopman J, Baltimore D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 1989; 63: 3708-3713.
24. Higashikawa F, Chang L. Kinetic analyses of stability of simple and complex retroviral vectors. Virology 2001; 280: 124-131.
25. Kulpa D, Topping R, Telesnitsky A. Determination of the site of first strand transfer during Moloney routine leukemia virus reverse transcription and identification of strand transfer-associated reverse transcriptase errors. EMBO J 1997; 16: 856-865.
26. Malmsten A, Ekstrand DH, Akerblom. L, et al. A colorimetric reverse transcriptase assay optimized for Moloney murine leukemia virus, and its use for characterization of reverse transcriptases of unknown identity. J Virol Methods 1998; 75: 9-20.
27. Roth MJ, Tanese N, Goff SP. Purification and characterization of murine retroviral reverse transcriptase expressed in Escherichia coli. J Biol Chem 1985; 260: 9326-9335.
28. Gotte M, Li X, Wainberg MA. HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch Biochem Biophys 1999; 365: 199-210.
29. Zhang WH, Hwang CK, Hu WS, Gorelick RJ, Pathak VK. Zinc finger domain of murine leukemia virus nucleocapsid protein enhances the rate of viral DNA synthesis in vivo. J Virol 2002; 76: 7473-7484.
30. Nisole S, Saib A. Early steps of retrovirus replicative cycle. Retrovirology 2004; 1: 9.
31. Cameron CE, Ghosh M, Le Grice SF, Benkovic SJ. Mutations in HIV reverse transcriptase which alter RNase H activity and decrease strand transfer efficiency are suppressed by HIV nucleocapsid protein. Proc Natl Acad Sci USA 1997; 94: 6700-6705.